RxDoctor Payments Data

L R Roberto Moscoso, MD

Cardiovascular Disease · Corona, CANPI 1073548962

Payments from drug & device makers

$5,640in general payments, 2019–2025

Across 289 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$729
  • AstraZeneca$686
  • Merck$534
  • Boehringer Ingelheim$499
  • Pfizer$334
  • Johnson & Johnson$323
  • plus $3K from 28 others

What the payments were for

  • Food & beverage$5,55398%
  • Education$872%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,640 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$263,699
Medicare patients
1,205
Services billed
3,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban396$414,521
EntrestoSacubitril/Valsartan174$174,845
XareltoRivaroxaban65$82,028
JardianceEmpagliflozin72$68,433
FarxigaDapagliflozin Propanediol30$35,130
MultaqDronedarone Hcl30$32,536
Repatha SureclickEvolocumab30$16,664
NexlizetBempedoic Acid/Ezetimibe14$10,062
Ezetimibe172$3,806
Atorvastatin Calcium428$3,667
Midodrine Hcl36$2,728
Metoprolol Succinate158$2,050
Amiodarone Hcl55$1,614
Rosuvastatin Calcium85$1,512
Potassium Chloride74$1,470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$334$414,521396 claims
NovartisEntresto$729$174,845174 claims
Johnson & JohnsonXarelto$323$82,02865 claims
Boehringer IngelheimJardiance$499$68,43372 claims
AstraZenecaFarxiga$686$35,13030 claims
Sanofi-aventis U.S. LLCMultaq$208$32,53630 claims
Esperion Therapeutics, Inc.Nexlizet$104$10,06214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →